Payment overview · 2025
General Payments
$207.17
12 reported records · 6 companies
Healthcare provider profile · identity verified
Corey D Hunt, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWBERRY, SC · NPI 1902997745
Verified facts
What the public records show
CMS Open Payments records show Corey D Hunt, MD received $207.17 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.65 | 33.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.43 | 28.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.61 | 15.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.90 | 8.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.93 | 7.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.65 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.17 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.55 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 601 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 121 |
| Lisinopril | Lisinopril | 285 | 73 |
| Metformin Hcl | Metformin Hcl | 261 | 62 |
| Valsartan | Valsartan | 254 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 61 |
| Omeprazole | Omeprazole | 217 | 66 |
| Chlorthalidone | Chlorthalidone | 203 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 182 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 44 |
| Gabapentin | Gabapentin | 154 | 43 |
| Alprazolam | Alprazolam | 152 | 19 |
| Losartan Potassium | Losartan Potassium | 151 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 44 |
| Simvastatin | Simvastatin | 146 | 46 |
| Famotidine | Famotidine | 145 | 44 |
| Glimepiride | Glimepiride | 137 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 16 |
| Furosemide | Furosemide | 124 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 37 |
| Potassium Chloride | Potassium Chloride | 119 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 35 |
| Carvedilol | Carvedilol | 117 | 31 |
| Tramadol Hcl | Tramadol Hcl | 117 | 27 |
| Allopurinol | Allopurinol | 108 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 48 |
| Meloxicam | Meloxicam | 103 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 14 |
| Pregabalin | Pregabalin | 92 | 15 |
| Trazodone Hcl | Trazodone Hcl | 78 | 19 |
| Metformin Hcl Er | Metformin Hcl | 74 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 15 |
| Prednisone | Prednisone | 70 | 38 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 21 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Jardiance | Empagliflozin | 64 | 12 |
| Lorazepam | Lorazepam | 64 | suppressed |
| Spironolactone | Spironolactone | 64 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 18 |
| Eliquis | Apixaban | 61 | 18 |
| Farxiga | Dapagliflozin Propanediol | 59 | suppressed |
| Naproxen | Naproxen | 59 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 18 |
| Estradiol | Estradiol | 56 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 15 |
| Ozempic | Semaglutide | 47 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | 12 |
| Indapamide | Indapamide | 35 | 13 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Ibuprofen | Ibuprofen | 26 | 13 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Finasteride | Finasteride | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.17 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error